Jefferies Raises Price Target on BioMarin Pharma (BMRN) to $120; Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Jefferies Raises Price Target on BioMarin Pharma (BMRN) to $120; Reiterates Buy
August 5, 2016 9:01 AM EDT
Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and lifted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $120.00 (from $107.00) following Q2 results and raised guidance.
Schimmer commented, "After the close, BMRN reported strong 2Q results and raised FY2016... More
August 4, 2016 4:08 PM EDT
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($2.61), may not compare to the analyst estimate of ($0.52). Revenue for the quarter came in at $300.1 million versus the consensus estimate of $278.16 million.
GUIDANCE:
BioMarin Pharma sees FY2016 revenue of $1.1-1.15 billion,... More
August 3, 2016 2:51 PM EDT
The Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Initial Claims - Street sees 264kContinuing Claims - no Street consensus
Earnings:
AAC Holdings (NYSE: AAC) - consensus EPS $0.23
AGCO Corp. (Nasdaq: AGCO) - consensus EPS $0.92
ANI Pharma (Nasdaq: ANIP) - consensus EPS $0.77
Acceleron Pharma (NYSE: XLRN) - consensus loss $0.50
Agios Pharma (Nasdaq:... More
